Skip to main content

Advertisement

Table 2 Characteristics of the evaluable survey population

From: Treatment adherence with the easypod™ growth hormone electronic auto-injector and patient acceptance: survey results from 824 children and their parents

  Total (N = 824) Treatment-naïve (n = 601) Treatment-experienced (n = 223)
Boys, n (%)a 462 (56.1) 358 (59.6) 104 (46.9)
Age, median (range), years 11 (1-18) 11 (1-18) 11 (2-18)
Indication, n (%)b    
   GHD 543 (66.4) 407 (68.1) 136 (61.8)
   TS 80 (9.8) 46 (7.7) 34 (15.5)
   CRF 14 (1.7) 10 (1.7) 4 (1.8)
   SGA 125 (15.3) 98 (16.4) 27 (12.3)
   Other 56 (6.8) 37 (6.2) 19 (8.6)
Administration of injectionsc    
   Child 315 (38.7) 224 (37.5) 91 (41.7)
   Parent 430 (52.8) 317 (53.1) 113 (51.8)
   Other 7 (0.86) 6 (1.01) 1 (0.46)
   Child and parent 59 (7.2) 46 (7.7) 13 (6.0)
   Parent and other 4 (0.49) 4 (0.67) 0
Number of scheduled injections per weekd    
   6 234 (29.3) 177 (30.2) 57 (26.9)
   7 564 (70.7) 409 (69.8) 155 (73.1)
  1. aOne child missing from the treatment-experienced group.
  2. bSix children missing: three each from the treatment-naïve and treatment-experienced groups.
  3. CNine children missing: four from the treatment-naïve group and five from the treatment-experienced group.
  4. dTwenty-six children missing: fifteen from the treatment-naïve group and eleven from the treatment-experienced group.
  5. CRF -- chronic renal failure; GHD -- growth hormone deficiency; SGA -- small for gestational age; TS -- Turner syndrome.